ClinicalTrials.gg
CompletedNCT02928978TBCRC042Updated Oct 16, 2026Results posted

Ruxolitinib for Premalignant Breast Disease

A Phase 2 interventional study of Ruxolitinib and Placebo (for Ruxolitinib) in Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia and Atypical Ductal Hyperplasia, sponsored by Julie Nangia. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Julie Nangia · Phase 2, Interventional, and Treatment

How we know

Updated Oct 16, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States — 31 open to participants now, 51 under way, 6 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · United States.

Enrollment
64th of 171
84 · median 51
Started
2018
with 9 others
Phase 2
60 of 210
9 open now
Registered
140th of 210
by date

Among the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, this one is the 64th largest by enrollment of the 171 interventional ones that give a count, is one of 10 that started in 2018, is one of 60 in phase 2, and was the 140th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

31 of the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, or all of them as a file.
02

Study summary

This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.

03

Conditions studied

  • Ductal Carcinoma In Situ
  • Atypical Lobular Hyperplasia
  • Atypical Ductal Hyperplasia
  • Lobular Carcinoma In Situ

Keywords

  • Premalignant Breast Disease
  • ALH
  • ADH
  • DCIS
  • LCIS
  • Breast Cancer Prevention
  • Ruxolitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a breast showing ADH (atypical ductal hyperplasia), ALH (atypical lobular hyperplasia), LCIS (lobular carcinoma in situ), or DCIS (ductal carcinoma in situ) requiring surgical excision. Microinvasive disease is allowed.

    • NOTE: Tissue from the diagnostic biopsy must be accessible/available for research correlates (i.e., a tissue block or \~10 unstained slides). Due to the nature of the study, fewer slides may be accepted with prior permission from the Protocol Chair if there is insufficient tissue.
  • Women and men age 18 and older.
  • Adequate hematologic and organ function, defined as follows:

    • ≥ 1500/mm3
    • ≥ 9.0 g/dL
    • levels >200 x 109/L
    • Total ≤ 1.5 x institutional (ULN)
    • /ALT ≤ 2.5 x institutional ULN
    • Alkaline phosphatase ≤ 5 x institutional ULN
    • > 50 mL/min as calculated by the Cockcroft-Gault method
  • Willing to not use concomitant strong inhibitors as this could interfere with the metabolism of ruxolitinib (i.e azole antifungals, clarithromycin, conivaptan, grapefruit juice, mibefradil, nefazodone, protease inhibitors, telithromycin).
  • Women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  • If the patient undergoes germline genetic testing, the results must be received prior to randomization, as the results may affect the surgical approach and, in turn, the date of surgical excision.
  • Patient understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Treatment with selective estrogen receptor modulators (SERMs) or aromatase inhibitors for breast cancer prevention within 1 year prior to starting study treatment.
  • Treatment with any other agents within 30 days of starting study treatment.
  • Current diagnosis of invasive breast cancer (current microinvasive disease is allowed), or previous history of invasive breast cancer diagnosed within the last 5 years.

NOTE: If previous history of ER+ invasive breast cancer diagnosed > 5 years ago, patient must be off endocrine therapy for at least 1 year prior to starting study treatment.

  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, end stage renal disease (ESRD), or psychiatric illness/social situations that would limit compliance with study requirements.
  • Women who are pregnant or nursing.
  • -positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ruxolitinib.
  • Prior or current treatment with a JAK inhibitor, for any indication.
  • Known active or C.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.

    Drug: Ruxolitinib

  • Placebo comparator
    Placebo

    Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).

    Drug: Placebo (for Ruxolitinib)

Interventions

  • tablet (taken by mouth)

    Also known as: Jakafi, INCB018424

  • DrugPlacebo (for Ruxolitinib)

    tablet (taken by mouth)

06

What researchers measure

Primary outcomes

  1. Change in Percent of Apoptotic Cells

    The percent of premalignant breast cells in apoptosis at the time of diagnosis will be compared to the percent of cells in apoptosis following treatment with 15 (+/- 5) days of ruxolitinib or placebo. The percent of apoptotic cells is calculated for each time point's corresponding evaluable lesion tissue sample as: 100\*(number of premalignant breast cells expressing the CC3 biomarker, as determined by CC3 staining/total number of premalignant breast cells in sample).

    Time frame: 15 days (+/- 5 days)

Secondary outcomes

  1. Proliferation/Apoptosis Biomarkers

    To determine the difference in change in proliferation/apoptosis biomarker levels between diagnosis and surgery as a function of ruxolitinib treatment versus placebo. Example biomarkers include: pSTAT5, TUNEL, Ki67, BclXL, Mcl1, Bcl2, PRLR, pSTAT3, and serum prolactin.

    Time frame: 15 days (+/- 5 days)

07

Results

Posted Oct 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneRuxolitinibPlacebo
Started4242
Completed3036
Not completed126
Withdrew: No residual lesion (adh, alh, lcis, or dcis) at surgery93
Withdrew: Disease progression found after starting study treatment01
Withdrew: Diagnostic tissue not available (unable to measure change in apoptosis)31
Withdrew: Change in surgery date led to early off-study01

Outcome measures

PrimaryChange in Percent of Apoptotic Cells

The percent of premalignant breast cells in apoptosis at the time of diagnosis will be compared to the percent of cells in apoptosis following treatment with 15 (+/- 5) days of ruxolitinib or placebo. The percent of apoptotic cells is calculated for each time point's corresponding evaluable lesion tissue sample as: 100\*(number of premalignant breast cells expressing the CC3 biomarker, as determined by CC3 staining/total number of premalignant breast cells in sample).

Time frame:
15 days (+/- 5 days)
Reported as:
Median · Percentage of cells
Change in Percent of Apoptotic Cells
Percentage of cellsRuxolitinibPlacebo
Change in Percent of Apoptotic Cells-1.50 (-8.00 to 4.50)0.00 (-5.00 to 4.25)
SecondaryProliferation/Apoptosis Biomarkers

To determine the difference in change in proliferation/apoptosis biomarker levels between diagnosis and surgery as a function of ruxolitinib treatment versus placebo. Example biomarkers include: pSTAT5, TUNEL, Ki67, BclXL, Mcl1, Bcl2, PRLR, pSTAT3, and serum prolactin.

Time frame:
15 days (+/- 5 days)

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were assessed for participants starting at initiation of study medication until 30 days since the last dose of study medication, up to 50 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib0/42 (0%)0/42 (0%)18/42 (42.9%)
Placebo0/42 (0%)1/42 (2.4%)23/42 (54.8%)
Most frequent serious events
Most frequent serious events
EventRuxolitinibPlacebo
Vestibular disorderEar and labyrinth disorders0/421/42
Most frequent other events
Showing 10 of 36
Most frequent other events
EventRuxolitinibPlacebo
HeadacheNervous system disorders8/428/42
PainGeneral disorders and administration site conditions4/427/42
NauseaGastrointestinal disorders3/425/42
DiarrheaGastrointestinal disorders1/424/42
Stomach painGastrointestinal disorders4/421/42
FatigueGeneral disorders and administration site conditions2/423/42
DizzinessNervous system disorders3/421/42
VomitingGastrointestinal disorders1/422/42
Upper respiratory infectionInfections and infestations0/422/42
Back painMusculoskeletal and connective tissue disorders1/422/42

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RuxolitinibPlaceboTotal
Mean58 ± 10.356 ± 10.757 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)RuxolitinibPlaceboTotal
Female424284
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RuxolitinibPlaceboTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American4812
White323264
More than one race000
Unknown or Not Reported415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RuxolitinibPlaceboTotal
Hispanic or Latino10919
Not Hispanic or Latino303363
Unknown or Not Reported202
Lesion type at baseline
Lesion type at baseline(Participants)RuxolitinibPlaceboTotal
DCIS262955
Non-DCIS161329
08

Study locations

8 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Harris Health System - Smith Clinic
    Houston, Texas 77054, United States
  • O'Quinn Medical Tower - McNair Campus; Dan L Duncan Comprehensive Cancer Center
    Houston, Texas 77054, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Aug 2024, 75 months.

Results were first posted in Oct 2026, 2 years 1 month after primary completion.

Of 36 phase 2 interventional studies under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 170. This study's 75 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2016
First posted
Oct 10, 2016
StartActual
May 13, 2018
Primary completionActual
Aug 29, 2024
CompletionActual
Sep 18, 2024
Results first posted
Oct 16, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change in ApoptosisNow Change in Percent of Apoptotic CellsTime frame: 15 days (+/- 5 days)
Oct 16, 2026
Documents
Show all 1 update
  1. Oct 16, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change in ApoptosisNow Change in Percent of Apoptotic CellsTime frame: 15 days (+/- 5 days)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02928978
Lead sponsor
Julie Nangia
Collaborators
Incyte Corporation, Translational Breast Cancer Research Consortium
Responsible party
Julie Nangia (Assistant Professor, Baylor Breast Care Center) — Sponsor-investigator
First posted
Oct 10, 2016
Start date
May 13, 2018
Primary completion
Aug 29, 2024
Completion
Sep 18, 2024
Results posted
Oct 16, 2026
Last update
Oct 16, 2026

Study contacts

Julie Nangia, M.D.
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion